Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer is a phase 2, interventional study registered as NCT05972655 by Sir Run Run Shaw Hospital, with a registry enrolment figure of 32 participants, started 2023-08-02 and due to reach its primary completion in 2024-08-20. Interventions recorded: Modified short-course radiotherapy; PD-1 antibody; Capecitabine; Oxaliplatin. Conditions listed: Low Rectal Cancer. Primary outcome: Pathological complete response (pCR) rate. Colorectal eligibility wording from the registry: "Patients diagnosed with low rectal cancer within 10 cm from the lower edge of the tumor to the anal verge by pelvic MRI and anorectoscopy, the clinical stage is cT2N+M0/cT3-4aN0/+M0, the lymph nodes are limited to the mesorectum, the circumferential resection margin is negative". Sites: China. No results are recorded here; the registry entry is the source.